AIRR - ANZCA Institutional Research Repository
Skip navigation
Please use this identifier to cite or link to this item:
Title: Pharmacokinetics and analgesic effectiveness of intravenous parecoxib for tonsillectomy ± adenoidectomy.
Authors: Tan, Lena
Taylor, E 
Hannam, Jacqueline A
Salkeld, Lesley
Salman, Sam
Anderson, BJ 
Issue Date: Dec-2016
Source: Paediatric anaesthesia 2016-12; 26(12): 1126-1135
Abstract: Few pharmacokinetic (PK) and pharmacodynamic (PD) data exist for COX-2 selective inhibitors in children. We wished to characterize the PKPD of parecoxib and its active metabolite, valdecoxib, in this population. Children (n = 59) were randomized to parecoxib 0.25 mg·kg-1, 1 mg·kg-1, and 2 mg·kg-1during tonsillectomy ± adenoidectomy. Samples (4-6 per child) were obtained from indwelling cannula over 6 h. A second group of inpatient children (n = 15) given 1 mg·kg-1contributed PK data from 6 to 24 h. Pain scores and rescue medication for the first group were recorded postoperatively for up to 24 h. PK data were pooled with those (10 samples/24 h) from a published study of children (n = 38) who underwent surgery. A three-compartment parent and one-compartment metabolite model with first-order elimination was used to describe data using nonlinear mixed effects models. An EMAXmodel described the relationship between dose and rescue morphine equivalents during recovery. Parecoxib PK parameter estimates were CLPARECOXIB19.1 L·h-1·70 kg-1, V1PARECOXIB4.2 L·70 kg-1, Q2PARECOXIB6.29 L·h-1·70 kg-1, V2PARECOXIB130 L·70 kg-1, Q3PARECOXIB6.02 L·h-1·70 kg-1, and V3PARECOXIB2.03 L·70 kg-1. We assumed all parecoxib was metabolized to valdecoxib with CLVALDECOXIB9.53 L·h-1·70 kg-1and VVALDECOXIB51 L·70 kg-1. There was no maturation of clearance over the age span studied. There were no differences in pain scores between groups on waking, discharge, 12 h, or 24 h. There were no differences in analgesia consumption over 24 h between groups for tramadol, fentanyl, and morphine rescue use. Fentanyl and morphine consumption, expressed as morphine equivalents (0.13 mg·kg-1) in the 0.25 mg·kg-1group, was greater than that observed in the 1 or 2 mg·kg-1groups (0.095 mg·kg-1) in PACU. Parecoxib 0.9 mg·kg-1in a 2-year-old, 0.75 mg·kg-1in a 7-year-old, and 0.65 mg·kg-1in a 12-year-old child achieves dose equivalence of 40 mg in a standard 70 kg person. Clearance maturation may occur in infants younger than the current cohort. Parecoxib doses above 1 mg·kg-1add no additional analgesia.
DOI: 10.1111/pan.13009
PubMed URL:
Journal Title: Paediatric anaesthesia
Type: Journal Article
Randomized Controlled Trial
Appears in Collections:Scholarly and Clinical

Show full item record

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.